{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:42:28Z","timestamp":1780994548268,"version":"3.54.1"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi250371-4\"><jats:title>Importance<\/jats:title><jats:p>Olanzapine as part of a 4-drug antiemetic regimen is highly effective at preventing nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC). National prescribing rates of olanzapine in eligible patients have, however, remained persistently low.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250371-5\"><jats:title>Objective<\/jats:title><jats:p>To describe efforts to increase the guideline-concordant use of olanzapine in patients receiving HEC in a statewide oncology collaborative.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250371-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The Michigan Oncology Quality Consortium (MOQC) is a collaborative of Michigan-based oncology practices whose mission is to advance the care of patients with cancer and their caregivers through comprehensive, patient- and practice-led quality improvement initiatives. Participants were patients receiving HEC at 38 MOQC member practices during an initiative from 2019 to 2023 to improve guideline-concordant inclusion of olanzapine as part of a 4-drug antiemetic regimen in HEC prophylaxis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250371-7\"><jats:title>Interventions<\/jats:title><jats:p>Interventions included performance audit and feedback to practices along with peer comparison, learning collaboratives of practices, education by experts at collaborative meetings, creation of patient-facing materials, and the addition of value-based reimbursement beginning in 2021. Measure performance was assessed using the American Society of Clinical Oncology\u2019s Quality Oncology Practice Initiative.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250371-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Proportion of patients receiving olanzapine for the first cycle of HEC as part of a 4-drug antiemetic regimen for chemotherapy-induced nausea and vomiting.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250371-9\"><jats:title>Results<\/jats:title><jats:p>Between 2019 and 2024, data were manually collected from the medical records of 8662 patients treated with HEC at 38 medical oncology practices at 71 sites across the state. Individual patient-level demographic data are not available from the QOPI database. For patients from years 2021 through 2024, the median (IQR) age was 62 (52-69) years; 4434 were female (65.5%); 814 were Black or African American (12.0%), 121 were Hispanic or Latino (1.8%), and 5385 were White (79.7%). The use of olanzapine as part of a 4-drug antiemetic increased from 7.2% in 2019 to 63.4% in 2024 (\u03c7<jats:sup>2<\/jats:sup><jats:sub>1<\/jats:sub>\u2009=\u2009553.61; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250371-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this quality improvement study of olanzapine prescribing in eligible patients, MOQC deployed quality improvement methods to increase the prescribing of olanzapine as part of a 4-drug regimen in patients receiving HEC, well above both the baseline and national levels of prescribing. This work suggests that efforts to improve patient care can be effective across diverse practice types, locations, and sizes in a statewide collaborative. Ongoing efforts include supporting change in those practices with low rates of prescribing and demonstrating the importance of this work for patient outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.10392","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T15:31:02Z","timestamp":1747841462000},"page":"e2510392","source":"Crossref","is-referenced-by-count":2,"title":["Increasing Olanzapine Prescribing for Patients Undergoing Highly Emetogenic Chemotherapy"],"prefix":"10.1001","volume":"8","author":[{"given":"Ashley M.","family":"Bowen","sequence":"first","affiliation":[{"name":"Michigan Oncology Quality Consortium, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Cloud","sequence":"additional","affiliation":[{"name":"Munson Healthcare, Traverse City, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Fadly","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute at McLaren Greater Lansing, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Gennette","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute at McLaren Greater Lansing, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Hector-Word","sequence":"additional","affiliation":[{"name":"Munson Healthcare, Traverse City, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann","family":"Hirth","sequence":"additional","affiliation":[{"name":"Henry Ford Health, Jackson, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Kier","sequence":"additional","affiliation":[{"name":"Munson Healthcare, Traverse City, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Kostoff","sequence":"additional","affiliation":[{"name":"Henry Ford Health, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Kuriakose","sequence":"additional","affiliation":[{"name":"Henry Ford Health, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binu","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Covenant Healthcare, Saginaw, Michigan"},{"name":"The Cancer and Hematology Centers, Grand Rapids, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houman","family":"Nourkeyhani","sequence":"additional","affiliation":[{"name":"Covenant Healthcare, Saginaw, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin","family":"Rana","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute at McLaren Greater Lansing, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keli","family":"DeVries","sequence":"additional","affiliation":[{"name":"Michigan Oncology Quality Consortium, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Mackler","sequence":"additional","affiliation":[{"name":"Michigan Oncology Quality Consortium, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Winsted","sequence":"additional","affiliation":[{"name":"Michigan Oncology Quality Consortium, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Voisine","sequence":"additional","affiliation":[{"name":"Michigan Oncology Quality Consortium, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Griggs","sequence":"additional","affiliation":[{"name":"Michigan Oncology Quality Consortium, Ann Arbor"},{"name":"University of Michigan Department of Medicine (Hematology\/Oncology) and Policy, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"16","key":"zoi250371r1","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.12968\/bjon.2016.25.S4","article-title":"Patient-practitioner perception gap in treatment-induced nausea and vomiting.","volume":"25","author":"Vidall","year":"2016","journal-title":"Br J Nurs"},{"issue":"5","key":"zoi250371r2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","article-title":"Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings.","volume":"15","author":"Cohen","year":"2007","journal-title":"Support Care Cancer"},{"issue":"2","key":"zoi250371r3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00520-006-0109-7","article-title":"The impact of chemotherapy-induced nausea and vomiting on health-related quality of life.","volume":"15","author":"Ballatori","year":"2007","journal-title":"Support Care Cancer"},{"key":"zoi250371r4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review.","volume":"99","author":"Sommariva","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"zoi250371r5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/annonc\/mdh110","article-title":"The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers.","volume":"15","author":"Ihbe-Heffinger","year":"2004","journal-title":"Ann Oncol"},{"issue":"14","key":"zoi250371r6","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","article-title":"Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting.","volume":"374","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"zoi250371r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102512","author":"Filetti","year":"2023","journal-title":"Cancer Treatment Reviews"},{"issue":"7","key":"zoi250371r8","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s00520-020-05935-7","article-title":"Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.","volume":"29","author":"Chow","year":"2021","journal-title":"Support Care Cancer"},{"issue":"5","key":"zoi250371r9","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00520-016-3075-8","article-title":"Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.","volume":"24","author":"Chiu","year":"2016","journal-title":"Support Care Cancer"},{"issue":"24","key":"zoi250371r10","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update.","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"zoi250371r12","doi-asserted-by":"publisher","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.","volume":"21","author":"Roila","year":"2010","journal-title":"Ann Oncol"},{"issue":"12","key":"zoi250371r13","doi-asserted-by":"publisher","first-page":"e1953","DOI":"10.1200\/OP.22.00389","article-title":"Slow uptake of an effective therapy: patterns of olanzapine prescribing for those receiving highly emetogenic chemotherapy.","volume":"18","author":"Childs","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"zoi250371r14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/chp.47","article-title":"Lost in knowledge translation: time for a map?","volume":"26","author":"Graham","year":"2006","journal-title":"J Contin Educ Health Prof"},{"issue":"11","key":"zoi250371r15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3928\/00220124-20151020-02","article-title":"SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.","volume":"46","author":"Ogrinc","year":"2015","journal-title":"J Contin Educ Nurs"},{"issue":"2","key":"zoi250371r17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/bjhc.2020.0189","article-title":"Putting improvement in everyone\u2019s hands: opening up healthcare improvement by simplifying, supporting and refocusing on core purpose.","volume":"27","author":"Kostal","year":"2021","journal-title":"Br J Health Care Manage"},{"issue":"1","key":"zoi250371r18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12875-022-01912-7","article-title":"Implementing an audit and feedback cycle to improve adherence to the Choosing Wisely Canada recommendations: clustered randomized trail.","volume":"23","author":"Singer","year":"2022","journal-title":"BMC Prim Care"},{"issue":"S2","key":"zoi250371r19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/1475-6773.13775","article-title":"Effect of peer comparison feedback, individual audit feedback or both to clinicians on opioid prescribing in acute care settings: A cluster randomized clinical trial.","volume":"56","author":"Navathe","year":"2021","journal-title":"Health Serv Res"},{"issue":"1","key":"zoi250371r20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12909-019-1735-3","article-title":"Changing prescribing behaviours with educational outreach: an overview of evidence and practice.","volume":"19","author":"Kunstler","year":"2019","journal-title":"BMC Med Educ"},{"issue":"2","key":"zoi250371r21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2125.2012.04397.x","article-title":"A systematic review of educational interventions to change behaviour of prescribers in hospital settings, with a particular emphasis on new prescribers.","volume":"75","author":"Brennan","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"zoi250371r22","first-page":"75","article-title":"Changing physician behavior: what works?","volume":"21","author":"Mostofian","year":"2015","journal-title":"Am J Manag Care"},{"issue":"17","key":"zoi250371r23","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1001\/jama.2019.14990","article-title":"Value-based purchasing and physician professionalism.","volume":"322","author":"Casalino","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"zoi250371r24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/1077558719856775","article-title":"Value-based provider payment initiatives combining global payments with explicit quality incentives: a systematic review.","volume":"77","author":"Cattel","year":"2020","journal-title":"Med Care Res Rev"},{"issue":"3","key":"zoi250371r25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10552-020-01376-z","article-title":"Revisiting time to translation: implementation of evidence-based practices (EBPs) in cancer control.","volume":"32","author":"Khan","year":"2021","journal-title":"Cancer Causes Control"},{"issue":"15","key":"zoi250371r26","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1001\/jama.282.15.1458","article-title":"Why don\u2019t physicians follow clinical practice guidelines? A framework for improvement.","volume":"282","author":"Cabana","year":"1999","journal-title":"JAMA"},{"issue":"31","key":"zoi250371r27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.2017.35.31_suppl.155","article-title":"Hospitalization costs for nausea and vomiting: a savings opportunity.","volume":"35","author":"Roeland","year":"2017","journal-title":"J Clin Oncol"},{"key":"zoi250371r11","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology-antiemesis. 2022. Accessed July 31, 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1415"},{"key":"zoi250371r16","unstructured":"American Society of Clinical Oncology. Quality oncology practice initiative. Accessed April 15, 2025. https:\/\/www.asco.org\/practice-patients\/quality-improvement\/quality-programs\/qopi"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2834352\/bowen_2025_oi_250371_1747250362.56224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T15:31:05Z","timestamp":1747841465000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2834352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.10392","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]}}}